

## Claims

1. A prophylactic or therapeutic agent for viral myocarditis, comprising as an active ingredient, 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivative, an individual optical isomer or a pharmaceutically acceptable salt thereof.
- 5 2. A prophylactic or therapeutic agent for viral myocarditis according to claim 1, wherein the viral myocarditis is caused by RNA virus or hepatitis virus.
3. A prophylactic or therapeutic agent for viral myocarditis according to claim 2, wherein the RNA virus is orthomyxovirus or picornavirus.
4. A prophylactic or therapeutic agent for viral myocarditis-related viral disease,  
10 comprising as an active ingredient, 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivative, an individual optical isomer or a pharmaceutically acceptable salt thereof.
5. A prophylactic or therapeutic agent for viral disease according to claim 4, wherein the viral myocarditis-related viral disease is caused by RNA virus or hepatitis virus.
- 15 6. A prophylactic or therapeutic agent for viral disease according to claim 5, wherein the RNA virus is orthomyxovirus or picornavirus.
7. A prophylactic or therapeutic agent for viral disease according to claim 4, wherein the viral disease is selected from the group consisting of viral hepatitis (hepatitis A, hepatitis B, hepatitis C, hepatitis E, hepatitis G), adenovirus infection, influenza,  
20 herpes infection, viral ncephalitis, cytomegalovirus infection, viral enteritis or viral pericarditis.
8. An agent for healing or preventing viral cytotoxic injury, comprising as an active ingredient, 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivative, an individual optical isomer or a pharmaceutically acceptable salt thereof.
- 25 9. Use of a compound selected from 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivative, an individual optical isomer or a pharmaceutically acceptable salt thereof for the preparation of a medicament intended for preventing or treating viral myocarditis-related viral disease in a patient.
10. Use according to claim 9 wherein the compound is selected from the group consisting  
30 of [2-[4-[(4 chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, its dihydrochloride salt or its levorotatory enantiomer; 2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid or its dihydrochloride salt;  
5-[4-[(aminocarbonyl)(hydroxy)amino]but-1-ynyl]-2-(2-[4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl]ethoxy)benzamide or a pharmaceutically  
35 acceptable salt thereof; and

N-{4-[4-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]-1-piperazinyl}ethoxy)phenyl]-3-butynyl}-N-hydroxyurea or a pharmaceutically acceptable salt thereof.